Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis

Elexacaftor-tezacaftor-ivacaftor (ELX/TEZ/IVA) is a triple combination drug therapy approved for individuals with cystic fibrosis (CF) who possess at least one copy of the F508del cystic fibrosis transmembrane conductance regulator (CFTR) variant. ELX/TEZ/IVA improves lung function and decreases the...

Descripción completa

Detalles Bibliográficos
Autores principales: Stekolchik, Elena, Saul, David, Chidekel, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674891/
https://www.ncbi.nlm.nih.gov/pubmed/36411821
http://dx.doi.org/10.1016/j.rmcr.2022.101775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674891/
https://www.ncbi.nlm.nih.gov/pubmed/36411821
http://dx.doi.org/10.1016/j.rmcr.2022.101775

Ejemplares similares